5045 Orbitor Drive, Building 11, Suite 400
L4W4Y4 Mississauga, Ontario, ca
+49 (9232) 88190-31
YM Biosciences responds to BBM Announcement
"We do not believe that an offer at this price would appropriately value the Company's assets," said David Allan, Chairman and CEO of YM BioSciences. "However, as a matter of its fiduciary responsibility to shareholders, the Board will review and consider any formal offers it receives."
In addition to net cash of more than CDN $52 million at September 30, 2008, YM BioSciences owns outright the rights to AeroLEF, a unique approach to the delivery of fentanyl for the treatment of patients with acute pain which is being prepared for late stage trials. The Company is also the licensee for the highly differentiated EGFR-targeting drug, nimotuzumab, for most of the major market territories including Japan, Europe and North America. Nimotuzumab is currently undergoing a YM sponsored trial in pediatric glioma in Canada and the US, while being advanced in several Phase III trials by YM's licensees and other companies advancing the drug internationally. Nimotuzumab is already approved for sale in a number of countries. YM believes it has sufficient cash resources to materially further advance nimotuzumab over the next 24 months in addition to the development of the drug internationally.
As at September 30, 2008 the Company had 58,216,309 common shares outstanding, of which 2,380,953 common shares are held in escrow to be released contingent upon the completion of certain milestones.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an email@example.com.